The systemic scleroderma treatment market is highly competitive due to vast unmet medical needs. Mergers and acquisitions, partnerships, and strategic alliances are some growth strategies large companies in the systemic scleroderma treatment market are adopting. For example, in 2017, Janssen Pharmaceutical Company – a subsidiary of Johnson and Johnson Services Inc., acquired Actelion Pharmaceuticals Ltd. to become the leading player in the field of pulmonary hypertension.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7023
Vast unmet medical needs for systemic scleroderma is one of the key factors spurring the systemic scleroderma treatment market. At present, off-label drugs such as the ones for symptomatic autoimmune disorders such as rheumatoid arthritis are used for the treatment of systemic scleroderma. This serves to fuel the development of small molecule combination therapies and targeted biologics, to present vast scope of growth for the systemic scleroderma treatment market.
North America stood at the fore in the systemic scleroderma treatment market in the recent past. Increasing penetration of biologics in developed countries is a key factor behind the growth of systemic scleroderma treatment market in North America.
Extensive efforts of researchers and sponsors who are focused on developing novel drug candidates at a rapid rate strengthens growth prospects of the systemic scleroderma treatment market. Development of drug candidates most of which are in the pipeline vary in terms of their type and mechanism of action. For example, in September 2020, Kadmon Holdings Inc. obtained Orphan Drug Designation by the U.S. FDA for its new drug, belumosudil – for the treatment of systemic scleroderma.
However, current unique challenges in drug development for systemic scleroderma hampers the growth of systemic scleroderma treatment market.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7023
Some of the key players operating in the global systemic scleroderma treatment market include names such as Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Pfizer Inc., Gilead Sciences Inc., Novartis AG, and Bayer AG.